Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Emily Y. Weng"'
Autor:
Valentyn Moskalenko, Nathan D. Pfeifer, Brett Haumann, Edmund J. Moran, Elad Kaufman, Glenn Crater, David A. Lombardi, David L. Bourdet, RW Lord, Ashley Woodcock, Jacky Woo, Dave Singh, Maxim Bogus, Tuan Nguyen, Rajeev Saggar, Emily Y. Weng
BackgroundLung-targeted anti-inflammatory therapy could potentially improve outcomes in patients with COVID-19. The novel inhaled pan-Janus kinase (JAK) inhibitor TD-0903 was designed to optimise delivery to the lungs while limiting systemic exposure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40423d33da822e5548c57baa4f6ff857
https://doi.org/10.1101/2021.03.09.21252944
https://doi.org/10.1101/2021.03.09.21252944
Autor:
RW Lord, Elad Kaufman, Nathan D. Pfeifer, Glenn Crater, Edmund J. Moran, Ashley Woodcock, Rajeev Saggar, Jacky Woo, Maxim Bogus, Dave Singh, David L. Bourdet, Tuan Nguyen, Emily Y. Weng, Valentyn Moskalenko, Brett Haumann, David A. Lombardi
Publikováno v:
Singh, D, Bogus, M, Moskalenko, V, Lord, R, Moran, E J, Crater, G D, Bourdet, D L, Pfeifer, N D, Woo, J, Kaufman, E, Lombardi, D A, Weng, E Y, Nguyen, T, Woodcock, A, Haumann, B & Saggar, R 2021, ' A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 ', European Respiratory Journal, vol. 58, no. 4, 2100673 . https://doi.org/10.1183/13993003.00673-2021
The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d23c90bcf978bfeadaa1468946ed9e
https://doi.org/10.1183/13993003.00673-2021
https://doi.org/10.1183/13993003.00673-2021
